OpenLB
Open Library of Bioscience
Advanced Search
Cancers
Apr 10, 2021;13 (8):

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients.

Elisabeth M Jongbloed, Teoman Deger, Stefan Sleijfer, John W M Martens, Agnes Jager, Saskia M Wilting
Author Information
  1. Elisabeth M Jongbloed: Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
  2. Teoman Deger: Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
  3. Stefan Sleijfer: Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
  4. John W M Martens: Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
  5. Agnes Jager: Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
  6. Saskia M Wilting: Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA Rotterdam, The Netherlands. ORCID
PMID: 33920135 DOI: 10.3390/cancers13081811

Abstract

Monitoring treatment response in metastatic breast cancer currently consists mainly of radiological and clinical assessments. These methods have high inter-observer variation, suboptimal sensitivity to determine response to treatment and give little insight into the biological characteristics of the tumor. Assessing circulating tumor DNA (ctDNA) over time could be employed to address these limitations. Several ways to quantify and characterize ctDNA exist, based on somatic mutations, copy number variations, methylation, and global circulating cell-free DNA (cfDNA) fragment sizes and concentrations. These methods are being explored and technically validated, but to date none of these methods are applied clinically. We systematically reviewed the literature on the use of quantitative ctDNA measurements over time to monitor response to systemic therapy in patients with metastatic breast cancer. Cochrane, Embase, PubMed and Google Scholar databases were searched to find studies focusing on the use of cfDNA to longitudinally monitor treatment response in advanced breast cancer patients until October 2020. This resulted in a total of 33 studies which met the inclusion criteria. These studies were heterogeneous in (pre-)processing procedures, applied techniques and design. An association between ctDNA and treatment response was found in most of the included studies, independent of the applied assay. To implement ctDNA-based response monitoring into daily clinical practice for metastatic breast cancer patients, sample (pre-) processing procedures need to be standardized and large prospectively collected sample cohorts with well annotated clinical follow-up are required to establish its clinical validity.

Keywords

circulating tumor DNA liquid biopsies metastatic breast cancer treatment response

References

Clin Cancer Res. 2006 Nov 1;12(21):6403-9 [PMID: 17085652]
Nat Commun. 2016 May 13;7:11579 [PMID: 27174596]
PLoS Med. 2020 Oct 1;17(10):e1003363 [PMID: 33001984]
Clin Cancer Res. 2017 Oct 1;23(19):5687-5695 [PMID: 28679771]
Oncol Lett. 2020 Feb;19(2):1551-1558 [PMID: 31966080]
Breast Cancer Res Treat. 2019 Oct;177(3):659-667 [PMID: 31297647]
Nat Genet. 2019 Oct;51(10):1450-1458 [PMID: 31570896]
Int J Cancer. 2015 Nov 15;137(10):2513-9 [PMID: 25994408]
Nature. 2017 Apr 26;545(7655):446-451 [PMID: 28445469]
Oncotarget. 2017 Jun 14;8(32):52142-52155 [PMID: 28881720]
Clin Cancer Res. 2019 Nov 15;25(22):6598-6605 [PMID: 31439579]
J Mol Diagn. 2018 Sep;20(5):686-702 [PMID: 29936259]
N Engl J Med. 2004 Aug 19;351(8):781-91 [PMID: 15317891]
Ann Oncol. 2019 Jun 1;30(6):945-952 [PMID: 30860573]
Cancers (Basel). 2019 Aug 14;11(8): [PMID: 31416207]
Cancer Cell. 2018 Sep 10;34(3):427-438.e6 [PMID: 30205045]
N Engl J Med. 2019 May 16;380(20):1929-1940 [PMID: 31091374]
Anticancer Res. 2010 Jun;30(6):2463-8 [PMID: 20651409]
Breast Cancer Res. 2020 May 28;22(1):56 [PMID: 32466779]
Int J Mol Sci. 2020 Dec 11;21(24): [PMID: 33322643]
Mol Oncol. 2018 Jun;12(6):925-935 [PMID: 29689598]
N Engl J Med. 2013 Mar 28;368(13):1199-209 [PMID: 23484797]
Clin Chem. 2020 Jan 1;66(1):149-160 [PMID: 31628139]
PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
J Mol Diagn. 2019 Jan;21(1):123-137 [PMID: 30296589]
J Clin Oncol. 2017 Mar;35(7):751-758 [PMID: 27870562]
Breast. 2020 Feb;49:261-266 [PMID: 31927339]
Sci Transl Med. 2015 Aug 26;7(302):302ra133 [PMID: 26311728]
Mol Oncol. 2017 Mar;11(3):295-304 [PMID: 28164427]
Nat Commun. 2017 Nov 6;8(1):1324 [PMID: 29109393]
Oncotarget. 2016 May 31;7(22):32504-18 [PMID: 27102299]
Cancer J. 2017 Sep/Oct;23(5):257-261 [PMID: 28926425]
Clin Cancer Res. 2016 Mar 1;22(5):1130-7 [PMID: 26500237]
Clin Chem. 2017 Feb;63(2):532-541 [PMID: 27940449]
Transl Oncol. 2020 Feb;13(2):321-328 [PMID: 31877464]
Clin Cancer Res. 2018 Dec 1;24(23):5860-5872 [PMID: 30082476]
Eur J Cancer. 2019 Jan;106:133-143 [PMID: 30528798]
Clin Cancer Res. 2015 Oct 15;21(20):4586-96 [PMID: 26085511]
Oncogene. 2020 Apr;39(14):2987-2995 [PMID: 32042112]
BMC Cancer. 2017 Mar 22;17(1):210 [PMID: 28330468]
Mol Oncol. 2021 Jan;15(1):57-66 [PMID: 33070443]
Oncotarget. 2016 Oct 4;7(40):66020-66031 [PMID: 27602761]
J Clin Oncol. 2014 Nov 1;32(31):3483-9 [PMID: 24888818]
BMC Cancer. 2010 May 20;10:217 [PMID: 20487521]
Biomed Res Int. 2015;2015:986024 [PMID: 26339655]
Nat Commun. 2018 Mar 1;9(1):896 [PMID: 29497091]
Int J Cancer. 2020 Mar 1;146(5):1359-1368 [PMID: 31241775]
Ann Intern Med. 2013 Feb 19;158(4):280-6 [PMID: 23420236]
Cancer Res. 2014 Apr 15;74(8):2160-70 [PMID: 24737128]
PLoS One. 2016 Oct 19;11(10):e0165023 [PMID: 27760227]
Lancet Oncol. 2020 Oct;21(10):1296-1308 [PMID: 32919527]
Cancer Discov. 2019 Mar;9(3):354-369 [PMID: 30518523]
Clin Chem. 2015 Jun;61(6):838-49 [PMID: 25896989]
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033819896331 [PMID: 32129154]
Nat Med. 2019 Dec;25(12):1928-1937 [PMID: 31768066]

Grants

  1. 12039/KWF Kankerbestrijding
Journal Article Review

Word Cloud

Similar Articles

Cited By